

**RECEIVED
CENTRAL FAX CENTER**

MAY 07 2007

CERTIFICATE OF FACSIMILE TRANSMISSION UNDER 37 C.F.R. §1.8

I hereby certify that this correspondence, totaling 1 page(s) including recited attachments, is being facsimile transmitted to the United States Patent and Trademark Office at facsimile no.: 571-273-8300 (Central number) on the below date:

Date: May 7, 2007 Name: K. Shannon Mirksich, Ph.D. (Reg. No. 36,675) Signature: K. S. Mirksich

**BRINKS
HOFER
GILSON
& LIONE**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Appln. of: Melikian, et al.

Appln. No.: 10/743,281

Filed: December 22, 2003

For: INHIBITORS OF HUMAN TUMOR-
EXPRESSED CCXCKR2

Attorney Docket No: 10709-63

Examiner: Sabiha Naim Qazi

Art Unit: 1616

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL

Attached is/are:

- Transmittal (in duplicate) and Amendment and Response.
 Return Receipt Postcard.

Fee calculation:

- No additional fee is required.
 Small Entity.
 An extension fee in an amount of \$ _____ for a _____-month extension of time under 37 C.F.R. § 1.136(a).
 A petition or processing fee in an amount of \$ _____ under 37 C.F.R. § 1.17(______).
 An additional filing fee has been calculated as shown below:

	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra	Small Entity		Not a Small Entity	
					Rate	Add'l Fee	or	Rate
Total		Minus			x \$25=		x \$50=	
Indep.		Minus			x 100=		x \$200=	
First Presentation of Multiple Dep. Claim					+\$180=		+\$360=	
					Total	\$	Total	\$

Fee payment:

- A check in the amount of \$ _____ is enclosed.
 Please charge Deposit Account No. 23-1925 in the amount of \$ _____. A copy of this Transmittal is enclosed for this purpose.
 Payment by credit card in the amount of \$ _____. (Form PTO-2038 is attached).
 The Director is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this paper (including any extension fee required to ensure that this paper is timely filed), or to credit any overpayment, to Deposit Account No. 23-1925.

Respectfully submitted,

May 7, 2007
Date

K. Shannon Mirksich
K. Shannon Mirksich, Ph.D. (Reg. No. 36,675)

**BRINKS
HOFER
GILSON**

BRINKS HOFER GILSON & LIONE

NBC Tower – Suite 3600, 455 N. Cityfront Plaza Drive, Chicago, IL 60611-5599

RECEIVED
CENTRAL FAX CENTER
MAY 07 2007

Our Case No. 10709-63

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **Melikian, et al.**)
Serial No. **10/743,281**)
Filing Date: **December 22, 2003**) Examiner: Sabiha Naim Qazi
For **INHIBITORS OF HUMAN TUMOR-**) Group Art Unit No. **1616**
EXPRESSED CCXCKR2)

AMENDMENT AND RESPONSE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir,

In response to the Office communication mailed April 4, 2007, Applicants elect claims 1-34 for prosecution. Further, Applicants provisionally elect the species of compound #57, and identify claims 1, 3, 5, 6, 10, 12, 13, 19-22, 24-27, 29-33, 36, and 38 as readable thereon. Applicants admit some confusion as to what the Office communication required as explained in the remarks section. To the extent that the Office believes that there are more than 2 inventions (those defined by (1) claims 1-34 and (2) claims 35-38), Applicants respectfully traverse.

Amendments to the Claims are reflected in the listing of claims which begins at page 2 of this paper. Remarks begin on page 17 of this paper.